Trials / Completed
CompletedNCT02398526
Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases
PARABO - Pain Evaluation in Radium-223 (Xofigo®) Treated mCRPC Patients With Bone Metastases - a Non-interventional Study in Nuclear Medicine Centers
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 363 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This observational prospective single arm cohort study is designed to assess pain and bone pain related quality of life of metastatic Castration Resistant Prostate Cancer (mCRPC) patients receiving Radium-223 in a real life nuclear medicine practice setting. In addition, overall survival, time to next tumor treatment (TTNT), time to first symptomatic skeletal event (SSE), course of blood counts, and safety will be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Radium-223 dichloride, (Xofigo, BAY88-8223) | Dosage and treatment duration according to the decision of the treating physician |
Timeline
- Start date
- 2015-03-19
- Primary completion
- 2020-05-20
- Completion
- 2020-07-15
- First posted
- 2015-03-25
- Last updated
- 2021-11-02
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02398526. Inclusion in this directory is not an endorsement.